Related Experiment Videos
[Clinical development of new molecular targeted therapeutics for cancer therapy]
1Third Dept. of Internal Medicine, University of Tokushima School of Medicine.
Abstract:
Recently much attention has been paid to clinical development of new drugs targeting the important molecules involved in cell growth, motility, invasion, metastatic formation of cancer cells and tumor angiogenesis. Among them, several drugs are designed to inhibit those activities, by which cancer growth and/or metastasis may be controlled. A major problem in developing new molecular targeted therapeutics is determining the optimal biological dose in Phase I studies. Appropriate surrogate markers should be employed to evaluate their therapeutic efficacy before entering the Phase III study. A future strategy to evaluate the efficacy of new drugs in combination with conventional anticancer therapy (surgery, radiotherapy and chemotherapy) is required. For this, careful consideration must be given to the design of clinical Phase III trials. This paper discusses the present status and future strategy for development of new molecular targeted therapeutics in clinics.
Insights
Developing new molecular targeted therapeutics requires careful dose determination and efficacy evaluation. Future strategies must integrate these drugs with conventional anticancer therapies for optimal clinical trial design.
Area of Science:
- Oncology
- Molecular Biology
- Clinical Pharmacology
Context:
- Focus on novel drugs targeting cancer cell growth, motility, invasion, metastasis, and tumor angiogenesis.
- Development of targeted therapies aims to control cancer progression and metastasis.
Purpose:
- Discuss the current status and future strategies for clinical development of molecular targeted therapeutics.
- Address challenges in determining optimal biological doses in Phase I studies.
- Highlight the need for surrogate markers to assess therapeutic efficacy before Phase III trials.
Summary:
- Molecular targeted therapeutics are crucial in cancer treatment, focusing on inhibiting key cancer cell activities.
- Determining the optimal biological dose in Phase I trials and evaluating efficacy using surrogate markers are critical challenges.
- Future clinical development requires strategic integration with conventional therapies and careful Phase III trial design.
Impact:
- Informs the strategic development of novel cancer therapeutics.
- Aims to improve the design and success rate of clinical trials for targeted cancer drugs.
- Facilitates the advancement of personalized cancer medicine through effective drug development pathways.